U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Oral GLP-1 drugs will fill a niche rather than displace injections, according to analysts. TD Cowen estimates that pills will ...

The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Over 2,000 Ozempic and Zepbound lawsuits allege life-threatening side effects as FDA updates warnings and courts weigh ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Lilly’s shares were impacted after a difficult month for its weight loss drug, A recent study showed the pill form of Lilly's ...

COPENHAGEN, DENMARK (Reuters) -Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug ...

Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up ...

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...